Physiologically based pharmacokinetic (PBPK) modeling is an approach to predicting drug
pharmacokinetics, using knowledge of the human physiology involved and drug …

Rational drug use in special populations is a clinical problem that doctors and pharma-cists
must consider seriously. Neonates are the most physiologically immature and vulnerable to …

Pediatric physiologically‐based pharmacokinetic (PBPK) models have broad application in
the drug development process and are being used not only to project doses for clinical trials …

Developmental changes in children can affect the disposition and clinical effects of a drug,
indicating that scaling an adult dose simply down per linear weight can potentially lead to …

With great interest we read the paper of Khalil and Läer on the concepts of physiologically
based pharmacokinetic (PBPK) modeling and its applications to pediatric drug development …

Increased regulatory demands for pediatric drug development research have fostered
interest in the use of modeling and simulation among industry and academia …

Introduction There is a need for structured approaches to inform on pharmacotherapy in
preterm neonates. With their proven track record up to regulatory acceptance …

The concept of physiologically based pharmacokinetic (PBPK) modeling was introduced
years ago, but it has not been practiced significantly. However, interest in and …

There has been a significant increase in the use of physiologically based pharmacokinetic
(PBPK) models during the past 20 years, especially for pediatrics. The aim of this study was …

Among pediatric patients, preterm neonates and newborns are the most vulnerable
subpopulation. Rapid developmental changes of physiological factors affecting the …